JP2019532092A5 - - Google Patents

Download PDF

Info

Publication number
JP2019532092A5
JP2019532092A5 JP2019522803A JP2019522803A JP2019532092A5 JP 2019532092 A5 JP2019532092 A5 JP 2019532092A5 JP 2019522803 A JP2019522803 A JP 2019522803A JP 2019522803 A JP2019522803 A JP 2019522803A JP 2019532092 A5 JP2019532092 A5 JP 2019532092A5
Authority
JP
Japan
Prior art keywords
alkyl
hydrogen
heteroatoms selected
substituted
alkoxy
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2019522803A
Other languages
English (en)
Japanese (ja)
Other versions
JP2019532092A (ja
JP7145850B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2017/058645 external-priority patent/WO2018081488A1/en
Publication of JP2019532092A publication Critical patent/JP2019532092A/ja
Publication of JP2019532092A5 publication Critical patent/JP2019532092A5/ja
Application granted granted Critical
Publication of JP7145850B2 publication Critical patent/JP7145850B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2019522803A 2016-10-28 2017-10-27 Il-12、il-23および/またはifnアルファ応答の調節剤として有用なヘテロ二環化合物 Active JP7145850B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662414158P 2016-10-28 2016-10-28
US62/414,158 2016-10-28
PCT/US2017/058645 WO2018081488A1 (en) 2016-10-28 2017-10-27 Heterobicyclic compounds useful as modulators of il-12, il-23 and/or ifn alpha responses

Publications (3)

Publication Number Publication Date
JP2019532092A JP2019532092A (ja) 2019-11-07
JP2019532092A5 true JP2019532092A5 (enExample) 2020-11-12
JP7145850B2 JP7145850B2 (ja) 2022-10-03

Family

ID=60263169

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2019522803A Active JP7145850B2 (ja) 2016-10-28 2017-10-27 Il-12、il-23および/またはifnアルファ応答の調節剤として有用なヘテロ二環化合物

Country Status (8)

Country Link
US (1) US10781215B2 (enExample)
EP (1) EP3532473B1 (enExample)
JP (1) JP7145850B2 (enExample)
KR (1) KR102477063B1 (enExample)
CN (1) CN110114357B (enExample)
ES (1) ES2895107T3 (enExample)
MA (1) MA46620A (enExample)
WO (1) WO2018081488A1 (enExample)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110300590A (zh) 2016-10-21 2019-10-01 林伯士拉克许米公司 Tyk2抑制剂及其用途
TW201940483A (zh) 2018-03-12 2019-10-16 美商艾伯維有限公司 酪胺酸激酶2介導的傳訊之抑制劑
TWI800696B (zh) * 2018-12-10 2023-05-01 美商美國禮來大藥廠 7-(甲基胺基)吡唑并[1,5-a]嘧啶-3-甲醯胺衍生物
CN111484480B (zh) * 2019-01-29 2023-08-11 上海翰森生物医药科技有限公司 一种多环类衍生物抑制剂、其制备方法和应用
SG11202110523XA (en) * 2019-03-26 2021-10-28 Ventyx Biosciences Inc Tyk2 pseudokinase ligands
WO2020222773A1 (en) 2019-04-30 2020-11-05 Celgene Corporation Combination therapies comprising apremilast and tyk2 inhibitors
CN114929226B (zh) 2019-11-08 2024-09-27 温缇克斯生物科学公司 Tyk2假激酶配体
CN114901659A (zh) * 2019-11-26 2022-08-12 施万生物制药研发Ip有限责任公司 作为jak抑制剂的稠合嘧啶吡啶酮化合物
CN116283993B (zh) * 2021-12-20 2024-05-03 艾立康药业股份有限公司 一种嘧啶类化合物及其制备方法和应用
CN117838699A (zh) * 2022-09-30 2024-04-09 北京大学 二取代嘌呤类化合物用于抗炎的用途

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7176214B2 (en) 2003-05-21 2007-02-13 Bristol-Myers Squibb Company Imidazo-fused oxazolo[4,5-β]pyridine and imidazo-fused thiazolo[4,5-β]pyridine based tricyclic compounds and pharmaceutical compositions comprising same
WO2008135232A1 (en) 2007-05-02 2008-11-13 Riccardo Cortese Use and compositions of purine derivatives for the treatment of proliferative disorders
EP2188292B1 (en) * 2007-08-08 2013-05-29 GlaxoSmithKline Intellectual Property Development Limited 2- [ (2-{phenylamino}-1h-pyrrolo [2, 3-d]pyrimidin-4-yl) amino]benzamide derivatives as igf-1r inhibitors for the treatment of cancer
AU2009233964B2 (en) 2008-04-07 2012-06-07 Irm Llc Compounds and compositions as protein kinase inhibitors
BRPI0910668A2 (pt) * 2008-04-22 2019-09-24 Portola Pharmaceutiacals Inc inibidores de proteína quinases
CA2890935A1 (en) * 2012-11-08 2014-05-15 Bristol-Myers Squibb Company Alkyl amide-substituted pyrimidine compounds useful in the modulation of il-12, il-23 and/or ifn.alpha.
AR094537A1 (es) 2013-11-07 2015-08-12 Bristol Myers Squibb Co COMPUESTOS DE PIRIDILO SUSTITUIDOS CON ALQUILAMIDA ÚTILES COMO MODULADORES DE LAS RESPUESTAS DE IL-12, IL-23 Y/O IFNa
ES2702126T3 (es) * 2013-12-10 2019-02-27 Bristol Myers Squibb Co Compuestos de imidazopiridazina útiles como moduladores de respuestas a IL-12, IL-23 y/o IFN alfa
TW201625620A (zh) * 2014-05-14 2016-07-16 美國科羅拉多州立大學 作為蛋白去乙醯酶抑制劑及雙蛋白去乙醯酶蛋白激酶抑制劑之雜環氧肟酸及其使用方法
CN110300590A (zh) * 2016-10-21 2019-10-01 林伯士拉克许米公司 Tyk2抑制剂及其用途

Similar Documents

Publication Publication Date Title
JP2017509689A5 (enExample)
JP2019530699A5 (enExample)
JP2017511357A5 (enExample)
JP2015514806A5 (enExample)
CY1124728T1 (el) Παραγωγα βενζοξαβορολης για τη θεραπεια βακτηριακων λοιμωξεων
JP2019518766A5 (enExample)
JP2020502268A5 (enExample)
JP2016536363A5 (enExample)
JP2019081762A5 (enExample)
JP2016536364A5 (enExample)
JP2016534134A5 (enExample)
JP2018529739A5 (enExample)
JP2016532715A5 (enExample)
JP2016501185A5 (enExample)
EA201690019A1 (ru) Производное аминотриазина и содержащая его фармацевтическая композиция
JP2015535277A5 (enExample)
JP2016506369A5 (enExample)
JP2016518328A5 (enExample)
JP2012140432A5 (enExample)
JP2017535614A5 (enExample)
RU2014140735A (ru) ПРОИЗВОДНЫЕ ПИРАЗОЛО[1, 5-a]ПИРИМИДИНА, КОМПОЗИЦИИ, СОДЕРЖАЩИЕ УКАЗАННЫЕ СОЕДИНЕНИЯ, И СПОСОБЫ ИХ ПРИМЕНЕНИЯ
JP2008505194A5 (enExample)
JP2016506958A5 (enExample)
JP2016521710A5 (enExample)
JP2016040262A5 (enExample)